HALO

Halozyme Therapeutics, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000

$130.91Close $15.4BMarket cap $61.63 – $131.1852-week range Nov 5, 2026Next report · after the close

Stage 2 Leader 16th of 68

Highlights

Strengths

In a stage-2 uptrend all 8 trend conditions pass
Leading the market RS 97 · stronger than 97% of stocks over 12 months
RS line at a 1-year high outperforming the S&P 500 more than at any point this year
Near its high at its 52-week high
Accumulation up-day volume 1.5× down-day volume over 50 sessions
Earnings growing EPS +43% year on year, faster than the quarter before (+12 pts)

Cautions

Extended 6.1 ATR above its 50-day average
Results soon Nov 5, 2026, in 4 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 6, 2026

Off 12-month high 0%

1wk 4.2% price change

1mo 18.6% price change

12-month return 103% market up 11% · its own up 90%

F-score 5 / 9 Mixed

Altman Z 5.24 Low risk

P/E 48.7× price / earnings

PEG — P/E / EPS growth

P/B 315.9× price / book

Earnings yield 2.7% EBIT / enterprise value

Cheaper than 33% of the market · expensive

Revenue growth 38% year on year

EPS growth 43% latest quarter · +12 pts

Sales growth 48% latest quarter · +5 pts

ROE 154% return on equity

Free cash margin 46% $644.6M FCF

D/E 43.89 long-term debt / equity

Net debt / EBITDA 4.2×

Interest cover —EBIT / interest

Piotroski tests

profitability slipped from last year
took on more long-term debt
short-term liquidity weakened
gross margin narrowed
profitable on its assets
generating cash from operations
profits backed by cash
no new shares issued
assets working harder

Trade setup

ATR% 2.5% $3.25 a day · 2×ATR $124.40

RS 97 / 99 vs the universe

Trend 8 / 8 trend template

Relative volume 0.6× vs 50-day average

Up/down volume 1.54 50 sessions

Implied move — no option chain · report Nov 5, 2026

Trend template · 8 of 8

Screen verdict

1 of 3 screens

Stage 2 Leader in mixed conditions
- RS 97
- Trend 8/8
- Off 12-month high 0%
- EPS growth +43% (accel +12 pts)
- Sales growth +48% (accel +5 pts)
- Altman Z 5.24 (low risk)

Warning signs

1 flagged

Heavily indebted Net debt is 4.2 times EBITDA — roughly 4 years of earnings before interest, tax and depreciation to repay borrowings in full.

Last reported Aug 6, 2026

Results reaction Aug 6, 2026+23% vs market2 sessions after results

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $1.4B +38% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $316.9M -29% on FY2024

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $644.6M +38% on FY2024

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Gross 84%
Net 23%
Free cash 46%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $2.0B net debt

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 117.78m -12.8% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$267.6M	$443.3M	$660.1M	$829.3M	$1.0B	$1.4B
Gross margin	84%	82%	79%	77%	84%	84%
Operating income	$144.3M	$275.9M	$267.5M	$337.6M	$551.5M	$469.0M
Net income	$129.1M	$402.7M	$202.1M	$281.6M	$444.1M	$316.9M
Net margin	48%	91%	31%	34%	44%	23%
Earnings per share	$0.91	$2.74	$1.44	$2.10	$3.43	$2.56
Free cash flow	$53.0M	$298.0M	$235.3M	$373.3M	$468.4M	$644.6M
Free cash margin	20%	67%	36%	45%	46%	46%
Cash	$147.7M	$118.7M	$234.2M	$118.4M	$115.8M	$133.8M
Long-term debt	$0	$787.3M	$1.5B	$1.5B	$1.5B	$2.1B
Shareholders' equity	$151.0M	$197.0M	$169.8M	$83.8M	$363.8M	$48.8M
Shares outstanding	135.03m	137.50m	135.15m	126.77m	123.14m	117.78m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 6, 2026	Quarterly ↗	Jun 30, 2026	37d
May 11, 2026	Quarterly ↗	Mar 31, 2026	41d
Feb 17, 2026	Annual ↗	Dec 31, 2025	48d
Nov 3, 2025	Quarterly ↗	Sep 30, 2025	34d
Aug 5, 2025	Quarterly ↗	Jun 30, 2025	36d
May 6, 2025	Quarterly ↗	Mar 31, 2025	36d
Feb 18, 2025	Annual ↗	Dec 31, 2024	49d
Oct 31, 2024	Quarterly ↗	Sep 30, 2024	31d
Aug 6, 2024	Quarterly ↗	Jun 30, 2024	37d
May 7, 2024	Quarterly ↗	Mar 31, 2024	37d
Feb 20, 2024	Annual ↗	Dec 31, 2023	51d
Nov 6, 2023	Quarterly ↗	Sep 30, 2023	37d

Current reports

Filed	Disclosed
Sep 30, 2026	Director or officer change ↗
Sep 22, 2026	Material agreement · New obligation · Unregistered share sale ↗
Sep 18, 2026	Other events ↗
Sep 16, 2026	Other events ↗
Aug 18, 2026	Director or officer change ↗
Aug 6, 2026	Results ↗
Jul 2, 2026	Director or officer change ↗
May 11, 2026	Results ↗
May 7, 2026	Shareholder vote ↗
Apr 30, 2026	Director or officer change ↗
Apr 24, 2026	Charter or bylaws ↗
Mar 12, 2026	Director or officer change ↗